Australia's most trusted
source of pharma news
Tuesday, 03 February 2026
Posted 3 February 2026 AM
AstraZeneca has come out swinging for the obesity market with a deal worth up to US$18.2 billion covering eight potential drug candidates.
The agreement with Hong Kong-based CSPC Pharmaceutical Group will see the pharmas initially progress four programs, including SYH2082, a once-monthly injectable dual GLP1/GIP receptor agonist progressing into Phase 1 trials.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.